Drug Information

General Information of This Drug
Drug ID DRG00027
Drug Name Indium-111
Synonyms
Indium-111; Indium In-111; 15750-15-9; 111In; 111In radioisotope; Indium, isotope of mass 111; Indium (111 In); E9NGC49E0T; UNII-E9NGC49E0T; In-111 radioisotope; INDIUM IN 111; INDIUM (111IN); INDIUM, IN-111; ISOTOPE OF MASS 111; INDIUM IN 111 [VANDF]; DB11916; INDIUM (111 IN) [WHO-DD]; Q6025171
   Click to Show/Hide
Target(s) Human Deoxyribonucleic acid (hDNA)  Target Info 
Structure
Formula
In
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 110.905
Lipid-water partition coefficient (xlogp) Not Available
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 0
Rotatable Bond Count (rotbonds) 0
PubChem CID
5462099
Canonical smiles
[In]
InChI
InChI=1S/In/i1-4
InChIKey
APFVFJFRJDLVQX-AHCXROLUSA-N
IUPAC Name
indium-111
Each Peptide-drug Conjugate Related to This Drug
Full Information of The Activity Data of The PDC(s) Related to This Drug
111In-DTPA-octreotide [Approved]
 PDC Info 
Obtained from the Model Organism Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Digestive system neoplasms
Efficacy Data Tumor cell uptake rate 47%
Administration Time 4 h
Administration Dosage 10 nM
MOA of PDC
In our previous study, d-Phe at position 1 in 111In-DTPA-d-Phe1-octreotide was replaced with Asp to minimize the change in molecular size. While the Phe3D-Trp4Lys5Thr6 sequence in octreotide is important for binding to the somatostatin receptor, the majority of octreotide derivatives with high somatostatin receptor affinity possess an N-terminal amino acid with an aromatic side chain, such as d-Phe or naphthylalanine. With these findings in mind, we designed, synthesized and evaluated not only the previously reported 111In-DTPA-Asp1-octreotide but also 111In-DTPA-Asp0-d-Phe1-octreotide, in which an Asp was incorporated between DTPA and N-terminal d-Phe in 111In-DTPA-d-Phe1-octreotide.

   Click to Show/Hide
Description
Figure 3 shows the results of cellular uptake experiments. When incubated with111In-DTPA-Asp1-octreotide, the uptake levels of radioactivity by AR42J cells were extremely low compared with those for111In-DTPA-d-Phe1-octreotide. In contrast, the uptake levels of111In-DTPA-Asp0-d-Phe1-octreotide increased in a time-dependent manner. The uptake levels of111In-DTPA-Asp0-d-Phe1-octreotide were not significantly different from those for111In-DTPA-d-Phe1-octreotide at 4h. For 111In-DTPA-Asp0-d-Phe1-octreotide, cell uptake experiments were conducted in the presence of varying concentrations of an unmodified octreotide. In Figure 4, uptake levels are shown as a percentage of the radioactivity level in the absence of the unmodified octreotide. The uptake levels of 111In-DTPA-Asp0-d-Phe1-octreotide were reduced in association with the concentration of the unmodified octreotide. The radioactivity uptake level was reduced by approximately 90% at 1 M concentration of the octreotide.

   Click to Show/Hide
In Vivo Model AR42J tumor-bearing mice model.
References
Ref 1 Design, synthesis and biological evaluation of negatively charged In-DTPA-octreotide derivatives. Bioorg Med Chem. 2014 Feb 15;22(4):1377-82. doi: 10.1016/j.bmc.2013.12.063. Epub 2014 Jan 8.